Valeo Pharma Launches Redesca and Redesca HP (LMHW biosimilar) in Canada

 Valeo Pharma Launches Redesca and Redesca HP (LMHW biosimilar) in Canada

Valeo Pharma Launches Redesca and Redesca HP (LMHW biosimilar) in Canada

Shots:

  • Valeo has started commercial shipment of Redesca and Redesca HP, its low molecular weight heparin (“LMWH”) biosimilar across Canada
  • The LMWH is being used primarily for treating and preventing deep vein thrombosis and pulmonary embolism and is now increasingly used as a 1L of defense tool in the fight against COVID-19
  • Redesca is a low molecular weight heparin biosimilar

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Valeo

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post